Vistagen Therapeutics (VTGN) Accumulated Depreciation & Amortization (2017 - 2025)
Vistagen Therapeutics (VTGN) has disclosed Accumulated Depreciation & Amortization for 12 consecutive years, with $150000.0 as the latest value for Q1 2025.
- Quarterly Accumulated Depreciation & Amortization rose 18.11% to $150000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $150000.0 through Mar 2025, up 18.11% year-over-year, with the annual reading at $150000.0 for FY2025, 18.11% up from the prior year.
- Accumulated Depreciation & Amortization hit $150000.0 in Q1 2025 for Vistagen Therapeutics, up from $127000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $153500.0 in Q1 2022 to a low of $31500.0 in Q2 2023.
- Historically, Accumulated Depreciation & Amortization has averaged $84883.3 across 5 years, with a median of $80900.0 in 2022.
- Biggest five-year swings in Accumulated Depreciation & Amortization: plummeted 96.75% in 2021 and later surged 120.14% in 2022.
- Year by year, Accumulated Depreciation & Amortization stood at $43700.0 in 2021, then surged by 120.14% to $96200.0 in 2022, then crashed by 67.26% to $31500.0 in 2023, then skyrocketed by 303.17% to $127000.0 in 2024, then increased by 18.11% to $150000.0 in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for VTGN at $150000.0 in Q1 2025, $127000.0 in Q1 2024, and $31500.0 in Q2 2023.